IMDZ Announces Filing Of New Lawsuit By Theravectys SA
Immune Design (Nasdaq: IMDZ) announced today that the day after it began trading on the Nasdaq Global Market, Theravectys SA ("TVS") filed a lawsuit against the company repeating claims that it had made in a prior lawsuit which TVS had earlier voluntarily dismissed.
TVS alleges that it has a contractual relationship with a Belgian manufacturer, Henogen, SA, which contained an exclusivity provision limiting Henogen's ability to manufacture certain lentiviral vectors for third parties and a provision preventing Henogen from sharing or using certain TVS confidential technology related to manufacturing processes developed by TVS with or for the benefit of others. TVS asserts that the company induced Henogen to breach its exclusivity obligations by manufacturing and supplying clinical batches of lentiviral vectors to the company and seeks monetary damages, as well as injunctive relief. TVS raises claims of tortious interference with contractual relations, misappropriation of trade secrets, unfair competition and unjust enrichment.
The causes of action in this lawsuit, which was filed in the Delaware Court of Chancery, are similar to the causes of action that were contained in the prior lawsuit filed by TVS against the company in October 2013 in the United States District Court for the District of Delaware. However, the current lawsuit adds the claim of unjust enrichment. The prior lawsuit was voluntarily dismissed by TVS in April 2014.
The company previously disclosed in the prospectus related to its initial public offering that TVS may refile a suit against the company.
The company is not currently using Henogen to manufacture its lentiviral vectors for its clinical trials. The company developed its own vector manufacturing process that it previously transferred to Henogen, and did not have any knowledge of TVS' processes. The company believes this lawsuit is without merit and intends to vigorously defend it.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.